Christian Boehringer to hand over as Chairman of the Shareholders’ Committee to Hubertus von Baumbach Shashank Deshpande, Member of the Board of ...

IT can’t sit back - the company’s 2,000 technology professionals must drive the identification of digital solutions to business problems. Line-of-business professionals must also feel comfortable and ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...

Boehringer Ingelheim licenses Cue Biopharma's CUE-501 bispecific antibody for $12M upfront, $345M in milestones to target ...

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address ...

Cue Biopharma (CUE) stock in focus as the company collaborates with Boehringer Ingelheim to develop CUE-501, for autoimmune ...

ELIAS Animal Health, a leading innovator in cancer immunotherapies for veterinary medicine, today announced that Dr. Philip J ...

Boehringer Ingelheim strengthens footprintin Swiss biotech innovation hub. Basel, Switzerland, Thursday, 03.04.2025 – Today NBETherapeutics (NBE)a wholly owned subsidiary of Boehringer Ingelheim ...

Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net sales Company prepares new product launches starting in 2025 Boehringer Ingelheim ...

A team at the Centro Nacional de Investigaciones Cardiovasculares ... The study was supported by funding from Fundación "la Caixa", the Boehringer Ingelheim Foundation, the National Institutes ...